Initial experience with long-acting risperidone microspheres injection

Australasian Psychiatry

Volumn 11, Issue 3, 2003, Pages 273-275

  Keks, Nicholas ^a   Been, Cyril ^a   D'Souza, Russell ^a   Thomas, Rajan ^a   Tune, Philip ^a   Babb, Jenny ^a   Brennan, Edwina ^a   Hope, Judy ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

Atypical antipsychotic; Depot injections; Risperidone

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; FLUPENTIXOL DECANOATE; LONG ACTING DRUG; MICROSPHERE; RISPERIDONE; ZUCLOPENTHIXOL DECANOATE;

ADULT; AKATHISIA; ALCOHOLISM; ARTICLE; CANNABIS ADDICTION; CLINICAL ARTICLE; DISEASE SEVERITY; DRUG ABUSE; DRUG FORMULATION; ERECTILE DYSFUNCTION; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; INJECTION; LONG TERM CARE; MALE; PARANOID SCHIZOPHRENIA; PARKINSONISM; PATIENT COMPLIANCE; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SIDE EFFECT; WEIGHT GAIN;

EID: 0142124274     PISSN: 10398562     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1665.2003.00577.x     Document Type: Article

References (7)

1. American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia. American Journal of Psychiatry 1997; 154 (Suppl. 4): 1-63.
2. Keks N, Altson K, Hope J et al. Use of antipsychotics and adjunctive medications by an inner urban community psychiatric service. Australian and New Zealand Journal of Psychiatry 1999; 33: 896-901.
3. Hope JD, Keks NA, Sacks TL, Freer T. Abnormal involuntary movements in people with schizophrenia in the community. Medical Journal of Australia 1999; 171: 111-112.
4. Janssen-Cilag. Risperdal Consta, Intramuscular Injection, Product Information (Approved by TGA 26 March 2003). North Ryde: Janssen-Cilag Pty Ltd, 2003.
5. Freyberger HJ, Eerdekens M, Mehnert A, Duchesne I. Patient satisfaction with their medication during long-term treatment with long-acting risperidone injection. International Journal of Neuropsychopharmacology 2002; 5 (Suppl. 1): S189.
6. Rubin RT, Hays SE. The prolactin secretory response to neuroleptic drugs: Mechanisms, applications and limitations. Psychoneuroendocrinology 1980; 5: 121-127.
7. Csernansky JG, Mahmoud MD, Brenner R. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. New England Journal of Medicine 2002; 346: 16-22.